1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

US FDA Explains How It Is Embracing Remote Assessments Post-Pandemic

 
• By Bowman Cox

Agency provides new details on plans for various remote methods of assessing manufacturing establishments that became popular when investigators were prevented by COVID-19 pandemic travel restrictions from visiting sites in person.

Virtual inspection
when the fda will show up remotely • Source: Shutterstock

The US Food and Drug Administration on 22 July said it will keep doing remote regulatory assessments of drug manufacturing plants, clinical investigator sites and other FDA-regulated establishments, even when the COVID-19 pandemic no longer prevents travel for site inspections – and provided some insight into why.

The experience the agency developed with various types of remote assessments during the public health emergency “has identified significant benefits...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Compliance

Lawyers Weigh In On ‘Sunshine’ Clause In EU Pharma Reform Package

 
• By Eliza Slawther

The Council of the EU has not taken forward a proposal from the European Parliament that would require companies to disclose the transfers of value they make to health care professionals and health care organizations – lawyers weigh in on the diverging proposals.

EU Pharma Overhaul May Reshape Aspects Of Drug Promotion And HCP Partnerships

 
• By Eliza Slawther

Lawyers explain how changes to rules around drug advertising and promotional activities under the EU pharma reform package could impact companies operating in the bloc, with one legal expert advising companies to “monitor developments closely.”

US FDA’s Tough Talk On Talc: Regulating In An Echo Chamber

 
• By Michael McCaughan

An FDA “expert roundtable” on talc produced a new talking point on a potential drug safety risk, but the basis of that claim is difficult to determine.